Cubit is an integrated immunoassay and molecular benchtop analyzer designed to simplify clinical workflows and expand the reach of high-quality diagnostics. Powered by proprietary extraction technologies and low-cost microfluidic solutions, the Cubit platform delivers actionable results exactly when and where they are needed — in 20 minutes or less.
True lab-quality sensitivity from the most challenging clinical samples. Low invalid rates and minimal system downtime.
One unified workflow for both immunoassay and molecular testing — eliminating the need for multiple platforms and complex testing protocols.
Designed to address a wide range of clinical needs — from infectious disease and women's health to respiratory, cardiology, and GI panels.
Actionable results in 20 minutes or less — enabling same-visit clinical decisions without the delays of traditional
lab-based workflows.
Less than 2 minutes of hands-on time with error-proof steps — designed for clinical settings without specialized laboratory training.
High-margin economics through efficient manufacturing costs and established reimbursement pathways — making quality diagnostics financially sustainable.
The Cubit platform is designed to serve a wide range of clinical needs across multiple specialties — with every new assay adding revenue to the same installed base.
From concept to real-world impact.
Development funding received from the Biomedical Advanced Research and Development Authority.
Successfully completed independent clinical evaluation validating platform performance.
First RADx grant received supporting platform feasibility and development.
NIH HCV grant awarded. Pre-Series A SAFE round closed. Platform build complete.
Expanded federal support recognizing the platform's public health impact.
We are pleased to receive funding from and collaborate with world-renowned organizations and innovators.
Learnmore about our mission-driven platform and the science powering the nextgeneration of point-of-care diagnostics.
Sponsored Research
Cubit is proud to work with select Universities to sponsor technology development and research projects. As part of this research, Cubit provides support for indirect costs up to a maximum rate of 20% of the total direct costs of the project. This maximum rate applies uniformly across all sponsored research projects.